Clemens-Martin Wendtner - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Clemens-Martin Wendtner

Showing results (101-110 of 106) with videos related to

Pageof 11

Sort By:

You have reached the last page of results.This site can display upto 106 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.

Blood|August 27, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.

The New England Journal of Medicine|May 10, 2023

First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.

Blood|May 12, 2023

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.

The New England Journal of Medicine|December 8, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.

Blood|March 30, 2026

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.

Pageof 11

Search research articles

Showing results (101-110 of 106) with videos related to

Sort By:

Pageof 11

You have reached the last page of results.This site can display upto 106 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.

Blood|August 27, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.

The New England Journal of Medicine|May 10, 2023

First-Line Venetoclax Combinations in Chronic Lymphocytic LeukemiaBarbara Eichhorst, Carsten U Niemann, Arnon P Kater, et al.

Blood|May 12, 2023

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinationsMoritz Fürstenau, Yvonne J Thus, Sandra Robrecht, et al.

The New England Journal of Medicine|December 8, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.

Blood|March 30, 2026

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trialMoritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht, et al.

Pageof 11